Literature DB >> 22973872

Lentiviral vectors: a versatile tool to fight cancer.

P U Emeagi1, C Goyvaerts, S Maenhout, J Pen, K Thielemans, K Breckpot.   

Abstract

Over the years, there has been an exponential increase in the number of gene therapy approaches that are under investigation for the treatment of cancer. This can be attributed to our growing understanding of the molecular mechanisms that contribute to the onset and maintenance of cancer as well as to the development of gene delivery vectors. In this review, we will focus on the use of lentiviral vectors (LVs) in immuno gene therapy of cancer, as these efficacious gene delivery vehicles have come to the fore front because of their many attractive features. LVs have been successfully applied to generate potent dendritic cell based anti-cancer vaccines and to deliver cancer-specific receptors to T-cells. Moreover, LVs are under investigation for the modulation of cancer cells. We will describe various strategies of this 'genuine' cancer gene therapy, amongst which transfer of suicide genes, modulation of pro- and anti-apoptotic molecules, strategies to optimize chemo- and radiotherapy, expression of molecules that affect angiogenesis or affect the immunogenicity of tumor cells. These will be discussed in view of our current knowledge of tumor immunology. Finally we will discuss some important issues and future directions to push the field forward.

Entities:  

Mesh:

Year:  2013        PMID: 22973872     DOI: 10.2174/1566524011313040011

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  8 in total

1.  Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses.

Authors:  Shuang Hu; Dipu Mohan Kumar; Chelsea Sax; Clayton Schuler; Ramesh Akkina
Journal:  Virology       Date:  2015-11-30       Impact factor: 3.616

2.  Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer.

Authors:  Weibing Zhou; Zhan Wang; Ni Shen; Weiwei Pi; Wuzhong Jiang; Juan Huang; Yuanping Hu; Xiong Li; Lunquan Sun
Journal:  Mol Cell Biochem       Date:  2014-09-16       Impact factor: 3.396

Review 3.  Role of non-classical MHC class I molecules in cancer immunosuppression.

Authors:  Grazyna Kochan; David Escors; Karine Breckpot; David Guerrero-Setas
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

4.  Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts.

Authors:  Yin Zhu; Ming Cheng; Zhen Yang; Chun-Yan Zeng; Jiang Chen; Yong Xie; Shi-Wen Luo; Kun-He Zhang; Shu-Feng Zhou; Nong-Hua Lu
Journal:  Drug Des Devel Ther       Date:  2014-12-09       Impact factor: 4.162

5.  Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.

Authors:  Kevin Van der Jeught; Patrick Tjok Joe; Lukasz Bialkowski; Carlo Heirman; Lidia Daszkiewicz; Therese Liechtenstein; David Escors; Kris Thielemans; Karine Breckpot
Journal:  Oncotarget       Date:  2014-10-30

Review 6.  Mesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend.

Authors:  Mehdi Karimi-Shahri; Hossein Javid; Alireza Sharbaf Mashhad; Shaghayegh Yazdani; Seyed Isaac Hashemy
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

7.  Lentiviral vector transduction of spermatozoa as a tool for the study of early development.

Authors:  Anil Chandrashekran; Ihsan Isa; Jayesh Dudhia; Adrian J Thrasher; Nicholas Dibb; Colin Casimir; Carol Readhead; Robert Winston
Journal:  FEBS Open Bio       Date:  2014-03-03       Impact factor: 2.693

Review 8.  The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.

Authors:  Cleo Goyvaerts; Karine Breckpot
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.